[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,40,77,105,143,178,203,231,256,283,303,331,371,396,421,444,472,496,515,547,571,591,613,646,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100618450","effect-of-tdcs-timing-on-motor-recovery-in-acute-stroke-rehabilitation-100618450",false,"NCT07331779","Effect of tDCS Timing on Motor Recovery in Acute Stroke Rehabilitation","Timing Matters: Comparing Pre , Peri , and Post Rehabilitation tDCS in Acute Stroke Recovery","Inclusion Criteria:\n\n* Hospitalization for stroke rehabilitation Hospitalized in a stroke rehabilitation unit at CHU de Liège.\n\nConfirmed acute stroke Diagnosis of acute stroke (ischemic or hemorrhagic) confirmed by neuroimaging, according to local clinical practice.\n\nTime since stroke In the acute\u002Fsubacute phase, as defined in the protocol (e.g., within X days\u002Fweeks after stroke onset) - to be specified exactly as in your protocol.\n\nAge Age ≥ 18 years.\n\nCapacity to consent Able to understand the study information and provide written informed consent.\n\nMotor impairment of the upper limb Presence of motor deficit of the upper limb on the affected side, sufficient to perform the WMFT tasks (according to protocol thresholds, if specified).\n\nMedically stable Clinically stable and judged by the treating physician as able to participate in daily rehabilitation and tDCS sessions.\n\nExclusion Criteria:\n\n* Contraindications to tDCS or cranial stimulation\n\nImplanted electronic devices in the head or neck (e.g., deep brain stimulator, cochlear implant, implanted neurostimulator, pacemaker with leads near the head).\n\nMetal implants in the skull (excluding dental fillings) in the area of stimulation.\n\nLarge skull defect or craniectomy over the stimulation site.\n\nHistory of seizures History of epilepsy or unprovoked seizures not adequately controlled, if considered a contraindication to tDCS by the investigator.\n\nSevere cognitive or communication impairment Severe cognitive impairment, aphasia, or comprehension difficulties preventing understanding of the study or execution of the tasks, as judged by the investigator.\n\nSevere comorbidities Unstable medical conditions (e.g., uncontrolled cardiac, respiratory, metabolic, or systemic disease) that could interfere with participation or increase risk.\n\nSevere psychiatric disorder Current severe psychiatric illness (e.g., psychosis, severe untreated major depression) that may affect cooperation or safety, as judged by the investigator.\n\nSkin conditions at electrode sites Skin lesions, infections, severe dermatitis, or wounds at or near the planned electrode placement sites.\n\nConcurrent participation in another interventional trial Participation in another interventional clinical trial that could interfere with the outcomes or safety of this study.\n\nPregnancy Pregnancy or breastfeeding, if considered a contraindication according to local tDCS safety policy (optional, depending on your protocol stance).\n\nAny other reason Any condition or circumstance that, in the opinion of the investigator, makes the patient unsuitable for the study or unable to comply with the protocol.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, double-blind, sham-controlled clinical trial investigates how the timing of transcranial direct current stimulation (tDCS) influences functional recovery during acute stroke rehabilitation. 198 hospitalized patients with confirmed acute stroke will be randomly assigned to one of three groups. Each day, all participants will receive three tDCS sessions: one before, one during, and one after their rehabilitation session. In each group, only one of these three daily stimulations is active, while the other two are sham, allowing a direct comparison of timing effects while maintaining blinding. All participants will complete 2 sets of five consecutive days of conventional rehabilitation combined with the tDCS protocol (2 weeks). Functional, sensory, psychological, and motor outcomes will be assessed at baseline and at the end of the intervention week. The study aims to determine whether the timing of tDCS application influences early post-stroke recovery and to inform the design of future confirmatory trials.",[27],"Acute Stroke","NOT_YET_RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"University of Liege","OTHER",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100630767","continuous-dual-aspiration-technique-with-zoom-system-for-stroke-100630767","NCT07491952","Continuous Dual Aspiration Technique With Zoom System for Stroke","Clinical Evaluation of Continuous Dual Aspiration Technique With Zoom System for Stroke (ADAPT 2.0)","ADAPT 2 0","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure\n3. Pre-stroke mRS 0-2\n4. Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use\n\nExclusion Criteria:\n\n1. Subjects with a life expectancy of less than 6 months\n2. Female subject who is known to be pregnant at time of admission\n3. Any intracranial hemorrhage in the qualifying head CT or MRI\n4. Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).\n5. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System\n6. Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study",{"count":49,"type":21},750,"OBSERVATIONAL","This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).",[53,27],"Ischemic Stroke",[55,56,57,58,59,60,61,62,63,64],"stroke","thrombectomy","Zoom","aspiration","reperfusion","mRS","ADAPT","continuous","dual aspiration","Zoom System","RECRUITING","2026-06-26",{"date":68,"type":32},"2026-06-29",{"date":70,"type":32},"2026-03-24",{"date":72,"type":21},"2030-06-01",{"name":74,"class":75},"Imperative Care, Inc.","INDUSTRY",16,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100374574","essential-acute-stroke-care-in-low-resource-settings-a-pilot-study-100374574","NCT04157231","Essential Acute Stroke Care in Low Resource Settings: a Pilot studY","Essential Acute Stroke Care in Low Resource Settings: a Pilot Study","EASY","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* A clinical or imaging-based diagnosis of acute stroke (ischemic or haemorrhagic) within 72 hours of stroke symptom onset\n* Provision of written informed consent\n* Subjects in observational, natural history and\u002For epidemiological studies not involving an intervention are eligible.\n\nExclusion Criteria:\n\n* Patients who have undergone intravenous thrombolysis or mechanical thrombectomy\n* Patients who are planned for transfer to the intensive care unit\n* Subarachnoid haemorrhage\n* Participation in an interventional medical investigation or clinical trial currently or within the past 3 months.",{"count":86,"type":21},300,[24],"An investigator-initiated, evaluator-blinded, prospective, multi centre, before-and-after, effectiveness-implementation hybrid design study to assess the feasibility of essential acute stroke care in a low resource setting",[27],[91,92,93,94],"Stroke","Ischemic stroke","hemorrhagic stroke","stroke package","2026-06-09",{"date":97,"type":32},"2026-06-11",{"date":99,"type":21},"2027-12-30",{"date":101,"type":21},"2030-12-30",{"name":103,"class":39},"The George Institute",4,{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":124,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":104},"100641032","effectiveness-of-best-care-practices-in-acute-stroke-in-conventional-hospitalization-best-care-ictushc-100641032","NCT07627399","Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)","Effectiveness of Implementing Best Care Practices in the Management of Patients With Acute Stroke in Conventional Hospitalization: A Cluster-Randomized, Open, Stepped-Wedge Controlled Trial.","BESTCAREICTUS","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke.\n* Admission to conventional hospitalization units (Internal Medicine) in regional hospitals without specialized Stroke Units.\n\nExclusion Criteria:\n\n* Patients admitted for a cause other than stroke who develop a stroke during their hospital stay (in-hospital stroke).\n* Patients subjected to invasive neurological procedures.\n* Patients undergoing invasive procedures, such as thrombectomy, who require transfer to a referral hospital and remain there for more than 48 hours.\n* Patients with deterioration of the level of consciousness that prevents the performance of dysphagia testing.\n* Patients that have been taken care of by Nurses and Nursing Assistants with \\>4 weeks of work experience in Stroke Units in the last 12 months",{"count":114,"type":21},700,[24],"The goal of this clinical trial is to evaluate whether a multicomponent nurse-led intervention (BEST CARE ICTUS\\_HC) can reduce stroke-related complications and improve recovery in adults (18 years and older) hospitalized with an acute ischemic or hemorrhagic stroke in hospitals without specialized Stroke Units. The main questions it aims to answer are:\n\n1. Does the implementation of the program increase the early and correct detection of swallowing difficulties (dysphagia) to prevent pneumonia?\n2. Does the program reduce the severity of attention problems (hemineglect) and improve the patients' quality of life up to 6 months after discharge?\n\nResearchers will compare patients receiving the BEST CARE ICTUS\\_HC program to patients receiving usual hospital care to see if this new approach improves patient safety and long-term functional recovery.\n\nParticipants will:\n\n* Receive either the usual hospital care for stroke or the BEST CARE ICTUS\\_HC nursing program, depending on the study phase of the hospital.\n* Be screened for swallowing problems using a standardized test before receiving any food or drink.\n* Be cared for in an adapted environment (FLECHA Project) that uses visual signs and room organization to help with orientation and safety.\n* Have their temperature, blood sugar, and blood pressure monitored under a strict specialized protocol.\n* Be contacted by phone 30 days and 6 months after leaving the hospital to answer questions about their health and quality of life.",[91,27,53,118,119,120,121,122,123],"Hemorrhagic Stroke","Cerebrovascular Disorders","Deglutition Disorders","Perceptual Disorders","Unilateral Neglect","Pneumonia, Aspiration",[27,125,126,122,127,128,129,130,131,132,133],"Nursing Care","Dysphagia Screening","Multicomponent Intervention","Care Bundle","Stepped-Wedge Design","Deglutition","Quality of life","Hyperglycemia","Fever","2026-05-29",{"date":136,"type":32},"2026-06-04",{"date":138,"type":32},"2026-05-12",{"date":140,"type":21},"2028-12",{"name":142,"class":39},"University of Malaga",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100444268","phase-2-treatment-of-acute-ischemic-stroke-remedy2-trial-100444268","NCT05065216","Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","Phase 2\u002F3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","ReMEDy2","Inclusion Criteria:\n\n1. Participant is between 18 and 90 years of age inclusive.\n2. Participant weight is 40 kg to 166 kg inclusive.\n3. Participant to be randomized and treatment initiated within 24 hours of last known normal\u002FAIS stroke onset.\n4. Participant has NIHSS ≥5 and ≤15 at approximately the time of randomization. This criterion also applies to participants who meet the following conditions:\n\n   * The participant initially presents with an NIHSS score below 5 but clinically worsens, including cases of progressing stroke \u002F stroke-in-evolution, resulting in a subsequent persistent NIHSS score of ≥5 and ≤15; and\n   * Participant meets all other inclusion and exclusion criteria, including repeat brain imaging to rule out hemorrhagic transformation.\n5. Participant had a pre-morbid mRS score of 0 to 1 (mRS score prior to AIS) as stated by participant or participant's representative.\n6. If participant has received fibrinolytic treatment for AIS within 4.5 hours of last know normal\u002FAIS stoke onset and at least 6 hours after completing fibrinolytic treatment, and the participant meets all of the following criteria:\n\n   * Participant's initial NIHSS score prior to fibrinolytics was ≤15; and\n   * At least six hours after fibrinolytics, the participant has NIHSS score of ≥5 and ≤15 with a persistent deficit; and\n   * The participant's NIHSS score showed less than a 4-point improvement, or worsened, after receiving fibrinolytics; and\n   * Participant meets all other inclusion and exclusion criteria including repeat brain imaging to rule out hemorrhagic transformation.\n7. Participant and\u002For legally authorized representative is able to provide informed consent.\n8. Participant is willing and able to comply with the study protocol, in the Investigator's judgment.\n\nExclusion Criteria:\n\n1. At screening, or with repeat imaging (see Inclusion 4 and 6), participant has imaging confirmed hemorrhage stroke.\n2. Participant has image findings with symptomatic large vessel occlusion at one or more of the following locations: Intracranial carotid I\u002FT\u002FL or M1 segment MCA, vertebral or basilar artery (BA).\n3. Participant has large core of established infarction defined as ASPECTS 0-5.\n4. Participant has or will receive MT for their current AIS.\n5. Participant has suspected or confirmed extracranial arterial dissection.\n6. Participant has imaging findings and\u002For symptoms consistent with a brain stem or cerebellar stroke. Posterior cerebral artery strokes without any associated brain stem or cerebellar involvement are allowable.\n7. Participant has any recorded SBP \\\u003C100 mmHg or MAP \\\u003C65 mmHg; MAP = DBP + \\[1\u002F3 (SBP - DBP)\\] (measured with noninvasive BP cuff type monitor) after stroke symptom onset and prior to randomization.\n8. Participant is currently prescribed angiotensin-converting enzyme inhibitor (ACEi) and is unable or unwilling to convert to another antihypertensive pharmacological treatment through Day 29 ±1 day (8 days after last treatment).\n9. Participant is currently prescribed an ACEi, and the last dose of the ACE inhibitor medication is reported to have been taken \\\u003C 24 hours before start of IV study drug infusion as stated by participant or participant's representative.\n10. Participant has a history of clinically significant allergic reactions such as angioedema or anaphylaxis requiring hospitalization.\n11. Participant has a diagnosis or suspected diagnosis of hereditary angioedema (HAE) or is taking or prescribed medications commonly used as prophylaxis\u002Ftreatment of HAE, such as C1-esterase inhibitors (Cinryze, Berinert, Ruconest, Haegarda), Danazol, kallikrein inhibitors (Ecallantide, Berotralstat, Lanadelumab), Bradykinin B2 Receptor Antagonists (Icatibant), or other medication designed to influence the kallikrein-kinin system.\n12. Life expectancy estimated at ≤1 year prior to enrollment.\n13. Participant has clinical evidence of an active infection at the time of enrollment requiring parenteral treatment or hospitalization to monitor or manage the infection.\n\n    NOTE: Treatment of uncomplicated infections with oral antibiotics would not be an exclusion (for example, the treatment of uncomplicated urinary tract infections or sinus infections with oral antibiotics would not be exclusionary).\n14. Participant has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).\n15. Participant is pregnant or nursing. NOTE: Participants who agree to stop nursing may be considered for inclusion at the discretion of the Investigator.\n16. Participants of child-bearing potential must agree to use medically acceptable contraceptive measures to prevent pregnancy. All participants of childbearing potential (defined as sexually mature participants who have had menses within the preceding 24 months and have not undergone permanent sterilization methods such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) must have a negative serum pregnancy test performed locally at screening. Participants of childbearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization. If participating in sexual activity that could lead to pregnancy, participants must use 2 reliable methods (1 per partner is acceptable) of contraception simultaneously while receiving protocol-specified medication and during the study follow-up period.\n\n    Participants participating in sexual activity must agree to use, or for their partner to use highly effective birth control methods (those with a failure rate of less than 1% per year when used consistently and correctly) until they have completed the study (after the Day 90 visit). Such methods include:\n    * Combined (estrogen and progesterone containing) hormonal oral, intravaginal, or transdermal contraception associated with the inhibition of ovulation\n    * Progesterone-only oral, injectable, or implantable hormonal contraception associated with the inhibition of ovulation\n    * Intrauterine device (IUD)\n    * Intrauterine hormone-releasing system (IUS)\n    * Bilateral tubal occlusion\n    * Vasectomized partner\n    * Sexual abstinence Participants who are not of reproductive potential (who have been postmenopausal for more than 24 consecutive months or have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) are not required to use contraception.\n\n    Participants are prohibited from sperm donation. NOTE: A negative serum pregnancy test will be documented during screening if a participant is of child-bearing potential.\n17. Participant is currently participating in or has participated in a study using an investigational device or drug or received an investigational drug or investigational use of a licensed drug within 30 days prior to screening.\n18. Participant does not have sufficient venous access for infusion of study treatment or blood sampling.\n19. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.\n20. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.","90 Years",{"count":153,"type":21},728,[155,156],"PHASE2","PHASE3","This is a Phase 2\u002F3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.",[27,53,91],[160,161,55,162,163,164,165,166,167],"acute","ischemic","AIS","tPA","LVO","MT","KLK1","Kallikreins","2026-04-23",{"date":170,"type":32},"2026-04-28",{"date":172,"type":32},"2021-11-07",{"date":174,"type":21},"2026-12",{"name":176,"class":75},"DiaMedica Therapeutics Inc",66,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100237493","sensory-motor-rehabilitation-post-stroke-100237493","NCT02369770","Sensory-Motor Rehabilitation Post Stroke","Inclusion Criteria:\n\n1. First time unilateral acute stroke, hemorrhagic or ischemic, 24 hours after admission in hospital to 1 year post stroke.\n2. Hemiplegia or hemiparesis\n3. Age 18-80\n4. Ankle impairments\n\nExclusion Criteria:\n\n1. No impairment or very mild ankle impairment of ankle.\n2. Unstable medical conditions that interferes with ability to training and exercise.\n3. Severe cardiovascular disorders that interfere with ability to perform moderate movement exercises.\n4. Cognitive impairment or aphasia with inability to follow instructions\n5. Pressure ulcer, recent surgical incision or active skin disease with open wounds present below knee of treated limb\n6. Severe pain in legs","80 Years",{"count":186,"type":21},140,[24],"Early after stroke, patients often have significant motor impairment and sensory deficit. Evidence has demonstrated heightened plasticity and significant recovery in the acute phase (first months) post stroke but there has been a lack of effective and practical protocols and devices for early intensive sensorimotor therapy.This research study will conduct a randomized clinical trial of an intensive motor-sensory rehabilitation on patients with acute stroke using a wearable rehabilitation robot. The primary aims are to facilitate sensorimotor recovery, reduce ankle impairments, and improve balance and gait functions. This clinical trial will be conducted on the Study and Control groups of acute stroke survivors.",[27],[27,191,192],"Robotic therapy","Ankle impairment","2026-04-17",{"date":195,"type":32},"2026-04-21",{"date":197,"type":32},"2019-04-26",{"date":199,"type":21},"2027-12-31",{"name":201,"class":39},"University of Maryland, Baltimore",1,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":211,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":50,"phases":4,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":202},"100375990","circulating-non-coding-rna-in-acute-ischemic-stroke-aisrna-100375990","NCT04175691","Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)","AISRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 72 hours of symptom onset\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n-a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases",true,{"count":213,"type":21},500,"90 Days","AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA\u002FmiRNA\u002FlncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.",[27,53],[218,219,220,221],"acute ischemic stroke","noncoding RNA","clinical significance","outcome","2026-04-10",{"date":224,"type":32},"2026-04-15",{"date":226,"type":32},"2019-11-24",{"date":228,"type":21},"2026-12-31",{"name":230,"class":39},"Nanjing First Hospital, Nanjing Medical University",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":239,"enrollmentInfo":240,"targetDuration":242,"studyType":50,"phases":4,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":202},"100492855","non-immunogenic-staphylokinase-in-reperfusion-therapy-of-ischemic-stroke-in-routine-clinical-practice-100492855","NCT05697575","Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","REPIN","Inclusion Criteria:\n\n* Age 18-85 ;\n* Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;\n* Thrombolytic therapy with the drug \"non-immunogenic staphylokinase\" is planned or has already been performed.\n\nExclusion Criteria:\n\n* Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;\n* The presence of a contraindication to thrombolytic therapy of ischemic stroke;\n* Pregnancy or lactation.","85 Years",{"count":241,"type":21},336,"1 Year","The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.",[27],[246,218,59],"stroke thrombolysis","2026-04-09",{"date":249,"type":32},"2026-04-13",{"date":251,"type":32},"2023-02-01",{"date":253,"type":21},"2030-05-10",{"name":255,"class":39},"National Society for Neurosonology and Cerebral Circulation",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":202},"100561371","body-composition-and-acute-stroke-100561371","NCT06589297","Body Composition and Acute Stroke","Prognostic Value for Predicting Functional Outcome Bioimpedancemetry and Temporal Muscle Measurement in Acute Stroke","PREDISTROKE","Inclusion Criteria:\n\n* volunteer stroke patients in acute phase\n* Age ≥ 18 years\n* Having had a brain MRI\n* Able to understand assessment guidelines\n* Not having objected to participate in the study after being duly informed\n\nExclusion Criteria:\n\n* Person under tutorship or curatorship\n* Person under court protection\n* Persons deprived of their liberty\n* Pregnant or breastfeeding women\n* Have a pacemaker or defibrillator",{"count":265,"type":21},250,[24],"Body composition appears to be a prognostic factor for the severity and functional outcome of stroke patients. In this study the prognostic value of two bioimpedance parameters will be studied (skeletal mass index and phase angle) and two temporal muscle measurements (thickness and surface area) to predict the functional outcome of patients at discharge and at 6 months",[27],[91,270,271,272,273],"Body composition","Bioimpedancemetry","Temporal muscle","Sarcopenia","2026-01-29",{"date":276,"type":32},"2026-02-02",{"date":278,"type":32},"2024-10-10",{"date":280,"type":21},"2028-06",{"name":282,"class":39},"Centre Hospitalier Régional d'Orléans",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":291,"studyType":50,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":202},"100620304","msoar-and-early-mortality-in-acute-stroke-100620304","NCT07355881","mSOAR and Early Mortality in Acute Stroke","The Modified SOAR Score as a Predictor of Early Mortality in Hospitalized Patients With Acute Stroke","Inclusion Criteria:\n\n* Patients diagnosed with acute stroke\n* Patients admitted to Sohag University Hospitals\n* Patients who underwent clinical evaluation\n* Patients who provided informed consent\n\nExclusion Criteria:\n\n* Patients with transient ischemic attack (TIA)\n* Patients with orthopedic conditions",{"count":20,"type":21},"7 Days","This observational study aims to evaluate the predictive accuracy of the Modified SOAR score for early mortality in patients with acute stroke. Adult patients presenting with acute stroke at Sohag University Hospitals will be included. Data on clinical presentation, medical history, and relevant laboratory investigations will be collected. The study will follow patients during their hospital stay to determine outcomes related to early mortality. The findings will help improve early risk stratification and management of acute stroke patients.",[27],"2026-01-26",{"date":296,"type":32},"2026-01-28",{"date":298,"type":32},"2025-11-01",{"date":300,"type":21},"2026-07-01",{"name":302,"class":39},"Sohag University",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":330},"100598010","impact-of-early-personalized-nutritional-management-on-1-month-mortality-after-acute-stroke-100598010","NCT07065929","Impact of Early, Personalized Nutritional Management on 1-month Mortality After Acute Stroke","Impact of Early, Personalized Nutritional Management on 1-month Mortality After Acute Stroke Pragmatic, Controlled, Multicenter, Cluster-randomized Trial","AVC-NUT2","Inclusion Criteria :\n\n* Patients ≥ 18 years of age\n* With an acute, ischaemic or haemorrhagic outpatient or inpatient stroke\n* NIHSS score ≥ 5\n* Hospitalised in a neurology department, or Neuro Vascular Unit (NVU), or in a department where beds are dedicated to receiving post-stroke patients\n* Stroke less than 2 days old\n* Anticipated length of hospital stay in a participating centre ≥ 5 days\n* Patient affiliated to or benefiting from a social security scheme\n* Patient or close relative having given written consent to participate in the study or patient included under the emergency procedure in the absence of contactable relatives\n\nExclusion Criteria:\n\n* Patients treated with nutritional therapy at the time of admission (history of bariatric surgery or gastrectomy, malabsorptive pathologies such as short bowel, extensive intestinal resections, etc.).\n* In a palliative situation where life expectancy is \\\u003C 3 months\n* Patient taking part in another study with an impact on mortality or nutrition\n* Previous inclusion in the trial\n* Pregnant, breast-feeding or parturient woman\n* Patient unable to follow the protocol for any reason\n* Patient deprived of liberty by judicial or administrative decision\n* Patient under compulsory psychiatric care\n* Person under legal protection\n* Poor understanding of the French language",{"count":312,"type":21},3084,[24],"This study evaluate the impact of early personalized nutritional management on 1-month mortality after acute stroke.\n\nIn the randomised centres of the interventional group (early personalized nutritional management), each patient will be assessed by a dietician within 2 days of stroke. Any swallowing problems are screened, and any barriers to eating are identified before dietary support. Patient's food intakes are recorded until the 7th day post-acute to assess their energy intake. Depending on patient's nutritional objectives, a reinforced feeding strategy comprising 2 levels is put in place, in order to prevent malnutrition: in level 1, the dietician tries to meet nutritional requirements orally, while in level 2 he can recourse to artificial nutrition in the event of failure or inability to meet requirements with oral intake alone. This strategy is started immediately after the initial assessment. Intakes are reassessed every 24 to 48 hours by the dietician in order to adapt the nutritional strategy as quickly as possible in order to cover the patient's personnalized nutritional needs.\n\nNo change in practice was required of the randomised centres in the control group.\n\nAll patients will be contacted by telephone 30 days after stroke to collect parts of the assessment criteria, while the other criteria will be collected directly from the patient's computerised medical record.\n\nThree months after stroke, an evaluation of quality of life and modified Rankin test will be performed.\n\nOur hypothesis is that the implementation of an individualized management of early nutritional support, aimed at compensating for the decrease in intake associated with the disease, would reduce mortality at 30 days in patients hospitalised for stroke.",[27],[317,318,319],"acute stroke","early nutrition","personalized dietary support","2026-01-06",{"date":322,"type":32},"2026-01-08",{"date":324,"type":32},"2025-09-19",{"date":326,"type":21},"2027-12",{"name":328,"class":329},"University Hospital, Angers","OTHER_GOV",12,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":338,"maxAge":184,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":202},"100579775","using-ai-systems-to-optimize-the-clinical-outcome-of-stroke-patients-100579775","NCT06828679","Using AI Systems to Optimize the Clinical Outcome of Stroke Patients","Personalized Rehabilitation Pathways to Maximal Motor Functional Return Through an AI Recovery Prediction System for Diverse Stroke Survivors","IInclusion Criteria:\n\n* Age 65-80\n* 1-6 months after onset of a first-time unilateral stroke rostral to midbrain\n* Moderate-to-severe motor impairment of one upper limb (Fugl-Meyer Assessment for Upper Extremity of 10-50 out of 66);\n* Able to provide written informed consent;\n* Detectable electromyographic (EMG) activities in flexor digitorum-flexor carpi radialis and extensor digitorum-extensor carpi ulnaris muscle groups, with EMG from each muscle group exceeding 3 standard deviations above baseline mean. This last criterion is essential for successful NMES training\n\nExclusion Criteria:\n\n* Unconscious or bed-bound;\n* Uncontrollable diabetes;\n* Anticipated non-adherence to treatment schedule;\n* On cardiac pacemaker;\n* Other severe comorbidities (heart\u002Fkidney failure, deranged liver function).","65 Years",{"count":340,"type":21},400,[24],"This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical\u002Foccupational therapists in Hong Kong through AI and precision rehabilitation. To reduce the socioeconomic burden from the stroke survivors' loss of independence and their care (\\>HK$15 billion\u002Fyear), the efficacy of rehabilitation and efficiency of its delivery must be improved. These goals can be achieved by prescribing them with individually tailored rehabilitations predicted to yield maximal functional return. Defining a predictive model for such personalization remains challenging given the immense heterogeneity of stroke. The investigators aim to build an explainable AI system that predicts a subject's recovery potential and the treatment option that may realize this potential based on multi-modal pre-rehab assessments. Data from clinical, neuroimaging, neurophysiological, and multi-omic evaluations will be collected from stroke survivors (N≥400) before they undergo upper limb rehab with usual care, neuromuscular stimulation, robotic training, or acupuncture. Machine learning-extracted data features will be used to train decision-tree and neural-network AI algorithms for robust predictions. As soon as the model is validated, the investigators will deploy it to implement a personalized rehab program in the community. Our model's ability to predict the optimal intervention from a wide spectrum of input modalities distinguishes ours from previous less-than-accurate models. Our interdisciplinary team of 13 PIs with expertise in neurology, PT\u002FOT, acupuncture, electrical\u002Fbiomed. engineering, robotics, neuroscience, neuroimaging, multi-omics, data science, and clinical trial management will put us in a world-unique position to execute this project successfully and generate opportunities of interdisciplinary education. In the long run, our prediction system will accelerate marketization of new rehab strategies by facilitating their clinical-trial evaluations in more targeted subjects, thereby leading Hong Kong to be a future global hub of innovative rehabilitation.",[344,27,345],"Acute Stroke Intervention","Acute Ischemic Stroke",[55,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361],"motor neuroscience","MRI","rehabilitation","muscle coordination","electromyography","Artificial intelligence","Transcranial Magnetic Stimulation","neuroimaging","Proteomics","Metabolomics","Genomics","Epigenomics","Acupuncture","biomarkers","muscle synergies","2025-12-19",{"date":364,"type":32},"2025-12-22",{"date":366,"type":32},"2025-07-01",{"date":368,"type":21},"2028-06-30",{"name":370,"class":39},"Chinese University of Hong Kong",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":385,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":394,"locationsCount":202},"100342374","seacoast-1--sedation-with-collateral-support-in-endovascular-therapy-for-acute-ischemic-stroke-100342374","NCT03737786","SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke","Title : SEACOAST 1 SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke 1: a Randomized Controlled Phase 2B Clinical Trial","SEACOAST","Inclusion Criteria:\n\n1. Age ≥18\n2. NIHSS ≥ 6 within 0-16h or NIHSS ≥ 10 within 16-24h\n3. Anterior circulation large vessel occlusion (ICA, M1, M2)\n4. ASPECTS score ≥ 6 within the first 6h, or DEFUSE trial imaging criteria within 6-16h; or DAWN trial clinical\u002Fimaging mismatch criteria within 16-24h\n5. Premorbid modified Rankin Scale (mRS) 0-2\n6. Patient deemed candidate for mechanical thrombectomy with anticipated groin puncture within 24 hours of last known well and within 90 min of ED arrival\n\nClinical Exclusion Criteria:\n\n1. Intubation in ED prior to anesthesiologist evaluation, or intubation for any other medical reason other than planned thrombectomy\n2. Rapid neurological improvement, suggestive of revascularization\n3. Known serious sensitivity to radiographic contrast agents.\n4. Current participation in another investigational drug or device treatment study.\n5. Renal Failure as defined by a serum creatinine \\> 2.0 mg\u002Fdl (or 176.8 μmol\u002Fl) or Glomerular Filtration Rate \\[GFR\\] \\\u003C 30.\n6. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason.\n7. Life expectancy of less than 90 days.\n8. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal\n9. Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow up assessments.\n10. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day.\n11. Septic or cardiogenic shock with severe life-threatening hypotension\n\nImaging Exclusion Criteria:\n\n1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of acute intracranial hemorrhage on presentation.\n2. CT or MRI evidence of mass effect or intracranial tumor (except small meningioma).\n3. CT showing hypodensity or MRI showing hyperintensity involving greater than 1\u002F3 of the middle cerebral artery (MCA) territory (or in other territories, \\>100 cc of tissue) on presentation.\n4. Baseline non contrast CT or DWI MRI evidence of a moderate\u002Flarge core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) \\\u003C 6\n5. CT or MRI evidence that ischemia is not in anterior circulation distribution.\n6. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate\u002Flarge infarct with poor collateral circulation, etc.).\n\nAnesthesia exclusion criteria (relative):\n\n1. History of Malignant Hyperthermia\n2. History of allergic reaction\u002Fanaphylaxis to anesthetic drugs\n3. Inability to tolerate supine position (severe CHF)\n4. Chronic O2 dependence or any other known pulmonary condition that might lead to difficult extubation and prolonged mechanical ventilation including known pulmonary hypertension","110 Years",{"count":381,"type":21},90,[24],"SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, with different forms of GA in patients with acute ischemic stroke due to anterior circulation large vessel occlusion (LVO) undergoing mechanical thrombectomy. The study compares GA with normocarbia (GAN) versus GA with mild hypercarbia (GAH), with a primary outcome of collateral robustness at measured at catheter angiography and clinical efficacy as secondary outcome. It is anticipated that the SEACOAST 1 will be followed by a larger, pivotal trial, SEACOAST 2, with primary clinical endpoints, in which the best method of GA identified in SEACOAST 1 is compared with the alternative strategy of anesthesia care (MAC) with minimal or no sedation. The current study focuses uppn SEACOAST 1, which is to be conducted in University of California, Los Angeles Ronald Reagan Medical Center and Santa Monica Medical Center. All acute stroke patients who arrive to one of these two stroke centers and are deemed eligible for thrombectomy will be considered for the proposed study. Physician-investigators will determine study eligibility. Informed consent to participate in the study will be obtained from legally authorized representatives or competent patients. For non-competent patients without on-scene legally authorize representatives, the consent process will utilize enrollment in emergency circumstances with exemption of informed consent (EFIC).",[27],[386,387,56,218],"large vessel occlusion","anesthesia","2025-12-18",{"date":390,"type":32},"2025-12-26",{"date":392,"type":32},"2019-11-28",{"date":174,"type":21},{"name":395,"class":39},"University of California, Los Angeles",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":403,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":202},"100613946","isolated-versus-synergetic-muscle-facilitation-on-upper-limb-functional-performance-in-acute-stroke-100613946","NCT07273201","Isolated Versus Synergetic Muscle Facilitation on Upper Limb Functional Performance in Acute Stroke","Effect of Isolated Versus Synergetic Muscle Facilitation on Upper Limb Functional Performance in Patients With Acute Stroke","Inclusion Criteria:\n\n* Unilateral Middle cerebral artery (MCA) stroke patients\n* Brunnstrom stage of recovery 1\\& 2\n* Normal body mass index (18.5 - 24.99 kg\u002Fm2)\n* Dominant handedness\n\nExclusion Criteria:\n\n* Perceptual, apraxia, major cognitive deficits\n* Recurrent stroke\n* Subjects with cerebellar lesions, painful or subluxated shoulder, any contracture or deformity of the upper extremity","50 Years","60 Years",{"count":406,"type":21},40,[24],"This study is a randomized controlled clinical trial that will be carried out to investigate the effect of isolated versus synergetic muscle facilitation on upper limb functional performance in patients with acute stroke.\n\nRESEARCH QUESTION:\n\nIs there a difference between isolated and synergetic muscle facilitation on upper limb functional performance in patients with acute stroke?\n\nIt will be hypothesized that:\n\nThere will be no difference between isolated and synergetic muscle facilitation on upper limb task-oriented training in patients with acute stroke.\n\nTreatment procedures:\n\nStudy group (A): patients will receive a physical therapy program in the form of a range of motion exercise, electrical muscle stimulation, stretching exercise, mental practice with motor imagery, and isolated muscle facilitation using electromyography (EMG) biofeedback for six weeks and followed by task-oriented training of the upper limb for six weeks control group (B): will receive a standard physical therapy program including range of motion exercise, electrical muscle stimulation, Mental practice with motor imagery and stretching exercise, synergetic muscle facilitation for six weeks, and followed by task-oriented training of the upper limb for six weeks.",[27],[411],"acute stroke, upper limb functional performance, muscle facilitation","2025-12-07",{"date":414,"type":32},"2025-12-09",{"date":416,"type":32},"2025-10-01",{"date":418,"type":21},"2026-07",{"name":420,"class":39},"Cairo University",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":211,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":433,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":202},"100322691","ischemic-conditioning-during-air-transport-save-penumbral-tissue-100322691","NCT03481205","Ischemic Conditioning During Air tRansport Save penUmbral Tissue","ICARUS","Inclusion Criteria:\n\n1. Age ≥18 and ≤ 80 years\n2. Suspected acute ischemic stroke with symptoms suggestive of large vessel occlusion (aphasia, agnosia, neglect, visual field cut, and gaze preference).\n3. Patient screened for rtPA, and rtPA administered if eligible\n4. Subject or legally authorized representative able to provide consent at the time of the assessment\n5. NIHSS 6-20\n\nExclusion Criteria:\n\n1. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural) on CT scan at the community hospital\n2. History of upper or lower extremity ischemia, known subclavian, brachial artery, iliac or femoral artery stenosis, subclavian steal syndrome, any upper or lower extremity soft tissue, orthopedic or vascular injury, or mastectomy or other procedure that may contraindicate taking blood pressure or having a cuff on the arm or leg for the conditioning treatment\n3. History of diabetes mellitus\n4. Enrollment in another clinical trial\n5. Patient incarcerated\n6. Pregnancy. Patients ages 18-55 will need to have a negative urine or blood based pregnancy test.\n7. Agitation deemed unsafe for ischemic preconditioning testing.\n8. Arteriovenous fistula in upper limb",{"count":429,"type":21},10,[24],"The purpose of this study is to demonstrate the feasibility of performing remote limb ischemic conditioning (RLIC) using the Doctormate device, a special blood pressure device used to perform RLIC, on patients with acute ischemic stroke due to large vessel occlusion being transported to a thrombectomy capable center by the helicopter.",[27],[434,386,435],"remote limb ischemic conditioning","helicopter transport","2025-11-05",{"date":438,"type":32},"2025-11-10",{"date":440,"type":32},"2020-06-01",{"date":228,"type":21},{"name":443,"class":39},"Enrique Leira",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":453,"studyType":50,"phases":4,"briefSummary":454,"conditions":455,"keywords":461,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":202},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":452,"type":21},60000,"5 Years","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[91,27,53,118,456,457,458,459,460],"Subarachnoid Hemorrhage","Cerebral Ischemia","Cerebral Infarction","Cerebral Stroke","Cerebral Vascular Accident",[91,27,53,118,457,458,459,460,462],"Stroke Recovery","2025-09-26",{"date":465,"type":32},"2025-10-02",{"date":467,"type":32},"2013-02-09",{"date":469,"type":21},"2028-09",{"name":471,"class":39},"University of California, San Francisco",{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":91,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":479,"maxAge":480,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":483,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":202},"100608631","mirror-therapy-for-hand-function-recovery-in-acute-stroke-100608631","NCT07204067","Mirror Therapy for Hand Function Recovery in Acute Stroke","Effectiveness of Mirror Therapy in Improving Motor Recovery and Hand Function in Patients With Acute Stroke A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 40-55 years\n* Acute ischemic or hemorrhagic stroke within the last 1 month\n* Unilateral hemiparesis\u002Fhemiplegia\n* Medically stable and cleared for rehabilitation\n* Able to follow verbal instructions; MMSE ≥ 24\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Recurrent stroke or bilateral involvement\n* Severe cognitive impairment (MMSE \\\u003C 24)\n* Visual field deficits, unilateral neglect, or severe aphasia interfering with MT\n* Other neurological disorders (e.g., Parkinson's, MS)\n* Orthopedic conditions affecting upper limb\u002Ftrunk\n* Uncontrolled cardio-respiratory disease limiting exercise\n* Severe spasticity (MAS ≥ 3) in affected limb\n* Concurrent enrollment in other interventional trials\n* Inability\u002Frefusal to consent","40 Years","55 Years",{"count":482,"type":21},44,[24],"Randomized controlled trial to determine whether mirror therapy (MT), added to conventional physiotherapy, improves upper-limb motor recovery, hand function, spasticity, and range of motion (ROM) in acute stroke compared with conventional physiotherapy alone. Outcomes include ARAT, Motor Assessment Scale, Modified Ashworth Scale, and goniometric ROM.",[27],[487],"Mirror Therapy Acute Stroke","2025-09-25",{"date":465,"type":32},{"date":491,"type":32},"2025-08-15",{"date":493,"type":21},"2027-09-17",{"name":495,"class":39},"Riphah International University",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":502,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":513,"locationsCount":202},"100429621","evaluating-potential-risk-of-choking-by-laryngeal-ultrasound-in-patients-with-acute-stroke-100429621","NCT04874454","Evaluating Potential Risk of Choking by Laryngeal Ultrasound in Patients With Acute Stroke","Inclusion Criteria:\n\n* acute stroke (in one month) patients\n\nExclusion Criteria:\n\n* patients with stroke occurring more than one month ago","20 Years",{"count":504,"type":21},200,[24],"The investigators evaluate the vocal cord movement in patients with acute stroke by ultrasound. The occurrence of choking or aspiration pneumonia will be collected in one year after the index stroke.",[27],"2025-09-15",{"date":324,"type":32},{"date":511,"type":32},"2023-07-14",{"date":228,"type":21},{"name":514,"class":39},"National Taiwan University Hospital",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":522,"maxAge":184,"enrollmentInfo":523,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":546},"100605825","phase-3-the-study-of-efficacy-and-safety-of-dimephosphon-in-acute-ischemic-stroke-100605825","NCT07167550","The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke","Multicenter, Randomized, Double-blind, Placebo-controlled Comparative Study of the Efficacy and Safety of the Drug Dimephosphon®, Concentrate for Solution for Intravenous Administration, 1 g, in Acute Ischemic Stroke Patients","Inclusion Criteria:\n\n1. Written informed consent was obtained from the patient or their legally authorized representative prior to study participation.\n2. Age 35-80.\n3. Patients must exhibit neurological manifestations consistent with acute ischemic stroke, with a documented onset-to-intervention interval ranging from 24 to 72 hours at the time of scheduled initial administration of the investigational drug.\n4. Verified by CT\u002FMRI current hemispheric ischemic stroke.\n5. NIHSS score ≥5 and ≤15 at screening.\n6. Ability to comply with all protocol-specified procedures, prohibitions, and restrictions.\n7. Willingness and ability to adhere to highly effective contraceptive methods as outlined in the study protocol.\n\nExclusion Criteria:\n\n1. Hemorrhagic stroke or hemorrhagic transformation of ischemic focus, traumatic brain injuries\n2. Vertebrobasilar stroke and\u002For development of acute insufficiency syndromes in the arteries of the vertebrobasilar system\n3. A patient with ischemic stroke who is a candidate for reperfusion therapy or who has undergone reperfusion therapy before participation in this study.\n4. The presence of anatomical abnormalities of the cerebral vessels (arteriovenous malformations, cavernous malformations, aneurysms, atresia of at least one of the extracranial arteries) according to the anamnesis or CT\u002FMRI data.\n5. Progression of neurological symptoms of stroke, defined as an increase in the NIHSS score by 4 points at the second assessment (immediately before randomization) from the value obtained at the first assessment (immediately after signing the informed consent form).\n6. Surgery on the carotid arteries less than 1 year before screening.\n7. History of stroke less than 1 year before screening.\n8. Myocardial infarction less than 6 months before screening.\n9. Chronic renal failure stage 2-3 (creatinine clearance less than 40 ml\u002Fmin).\n10. Pregnancy or lactation.\n11. Participation in another trial within 28 days prior to enrollment.\n12. Use of prohibited medications.","35 Years",{"count":524,"type":21},184,[156],"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dimephosphon® in acute ischemic stroke",[91,27,53,119,528],"Physiological Effects of Drugs",[530,531,532,533,534,535,27,53,536],"Neuroprotective Agents","Protective Agents","Neuroprotection","Anti-acidemic agents","Dimephosphon","Dimethyloxobutylphosphonyldimethylate","Antioxidants","2025-09-10",{"date":539,"type":32},"2025-09-11",{"date":541,"type":21},"2025-09-06",{"date":543,"type":21},"2026-04-30",{"name":545,"class":75},"Tatchempharmpreparaty, JSC",6,{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":567,"leadSponsor":569,"locationsCount":202},"100603611","role-of-mri-in-the-early-diagnosis-and-management-of-acute-stroke-and-its-impact-on-turnaround-time-in-emergency-settings-100603611","NCT07138768","Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Settings","The Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time (TAT) in Emergency Settings","Inclusion Criteria:\n\n* Age ≥18 years.\n* Both sexes.\n* Patients with acute stroke who are admitted to the emergency department.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or computed tomography (CT).\n* Symptoms strongly suggestive of subarachnoid hemorrhage.\n* Initiation of antithrombotic or thrombolytic treatment before the completion of both scans.\n* Inability to complete both scans in time to allow thrombolytic treatment within three h of the onset of symptoms.\n* Uncontrollable hypertension.\n* Pregnant or lactating women.",{"count":555,"type":21},136,"This study aims to evaluate the role of stroke protocol in the early diagnosis and management of acute stroke and its effect on turnaround time (TAT) in emergency settings.",[558,559,560,27,561,562],"Magnetic Resonance Imaging","Diagnosis","Management","Turnaround Time","Emergency Settings","2025-08-23",{"date":565,"type":32},"2025-08-26",{"date":563,"type":32},{"date":568,"type":21},"2026-12-01",{"name":570,"class":39},"Tanta University",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":579,"conditions":580,"keywords":581,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":202},"100599792","factors-and-preferences-in-patient-selection-of-rehabilitation-care-following-acute-stroke-a-predictive-correlational-study-100599792","NCT07089095","Factors and Preferences in Patient Selection of Rehabilitation Care Following Acute Stroke: A Predictive Correlational Study.","Factors and Preferences in Patient Selection of Rehabilitation Care Following Acute Stroke","Inclusion Criteria:\n\n* Age≧18 years old.\n* Patients with stroke (International Classification of Disease, ICD 10th edition I60-I68, G45-G46) diagnosed by physicians within 2 weeks after the onset of stroke, including the first and second strokes.\n\nExclusion Criteria:\n\n* Those with a score of 5 on the Modified Rankin Scale (mRS).\n* Those who have been accepted as research subjects have been admitted to hospital again for stroke.\n* People living in rehabilitation wards.\n* Those with unstable vital signs.\n* Those receiving palliative care or care.\n* Patients or family members who cannot communicate in Chinese or Taiwanese.",{"count":86,"type":21},"Background and Purpose Patients with stroke have to receive the rehabilitation care after medical condition has stabilized. In recent years, the long-term care policy offers more options available for rehabilitation care after stroke. However, the selection of care is mainly based on physcicians' advice. This study explores the factors and preferences in patient selection of rehabilitation care following acute stroke, in order to help clinical health professionals incorporate patients' preferences in patient-centred care to properly arrange the stroke rehabilitation care.\n\nMethods This is a cross-sectional and predictive study. Purposive sampling of patients surviving acute stroke is taken in the general ward of a medical center in northern Taiwan. Data are collected with patients' characteristics, National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Modified Rankin Scale (mRS), and factors and preferences in patient selection of rehabilitation care questionnaire. Data are analyzed using IBM SPSS 26.0 for windows. Demographic and clinical characteristics, family support systems and health care systems are compared between patients' preference in the selections of rehabilitation care. Variables with p \\\u003C .05 are included as potential predictor variables in the subsequent logistic regression analysis. The level of statistical significance is set at α=0.05.\n\nExpected results Demographic and clinical characteristics, family support systems and health care systems are expected as potential predictors of patients' preference in the selection of rehabilitation care.",[27],[582],"patient preferences","2025-07-20",{"date":585,"type":32},"2025-07-28",{"date":587,"type":32},"2023-05-11",{"date":589,"type":21},"2025-07-25",{"name":514,"class":39},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":4,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":598,"enrollmentInfo":599,"targetDuration":4,"studyType":22,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":202},"100567912","the-effects-of-chin-tuck-against-resistance-exercise-on-acute-stroke-patients-with-dysphagia-100567912","NCT06674356","The Effects of Chin Tuck Against Resistance Exercise on Acute Stroke Patients With Dysphagia","The Effects of Chin Tuck Against Resistance Exercise on Swallowing Function, Depression, and Quality of Life in Acute Stroke Patients With Dysphagia","Inclusion Criteria:\n\n1. Patients diagnosed with hemorrhagic or ischemic stroke, including those with initial diagnoses or recurrent strokes.\n2. Patients who did not pass the swallowing screening based on the standard swallowing scale.\n3. Adults aged 18 years and older.\n4. Vital signs are stable: systolic blood pressure (hemorrhagic \\\u003C 160 mmHg, ischemic \\\u003C 220 mmHg), heart rate 40-130 beats per minute, and oxygen saturation \\> 92%.\n5. The patient's consciousness is clear, able to express themselves, can communicate in Mandarin or Taiwanese, and can follow commands to perform actions.\n6. The patient can be in a seated position.\n\nExclusion Criteria:\n\n1. Patients who have had a stroke for more than one month (inclusive).\n2. Patients with a history of depression or related mental health disorders.\n3. Patients with a history of neck pain, injury, or disease.\n4. Patients who have previously undergone tracheostomy or have a tracheostomy tube in place.","100 Years",{"count":600,"type":21},74,[24],"The aim of this study is to investigate the effects of chin tuck against resistance exercise on swallowing function, depression, and quality of life in acute stroke patients with dysphagia.",[27,604],"Dysphagia","2025-05-08",{"date":607,"type":32},"2025-05-14",{"date":609,"type":32},"2024-12-22",{"date":611,"type":21},"2027-10",{"name":514,"class":39},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":629,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":645},"100574728","phase-3-the-fifth-intensive-preventing-secondary-injury-in-acute-cerebral-haemorrhage-trial-within-act-global-100574728","NCT06763055","The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL","INTERACT5","Inclusion Criteria:\n\n1. Age between 18 and 80 years old\n2. Diagnosis of presumed spontaneous supratentorial intracerebral haemorrhage, confirmed by brain imaging\n3. Presentation to hospital within 24 hours of symptom onset (or last seen well)\n4. Hematoma volume ≥10 mL or any volume post-surgery\n5. NIHSS score \\>8\n6. GCS ≥8\n7. Provide written informed consent by patient (or approved surrogate)\n\nExclusion Criteria:\n\n1. Secondary cause of haemorrhage (e.g., structural abnormality such as arteriovenous malformation, cerebral aneurysm, tumour, trauma), or haemorrhagic transformation of acute ischaemic stroke\n2. Isolate intraventricular haemorrhage\n3. Chronic Kidney Disease\n4. Very high likelihood of death within 7 days or poor adherence to study treatment or follow-up\n5. Severe comorbid disease that will interfere with outcome assessments (e.g., cancer, chronic airflow disease, heart failure, significant disability)\n6. Women who are pregnant or lactating\n\n   Exclusion Criteria related to use of deferoxamine:\n7. Previous chelation therapy or known hypersensitivity to deferoxamine products;\n8. Severe iron deficiency anaemia (haemoglobin \\\u003C7 g\u002FdL or requiring regular blood transfusions);\n9. Taking iron supplements containing \\>325 mg of ferrous iron;\n10. Serum creatinine \\>2 mg\u002FdL;\n11. Patients with known heart failure taking \\>500 mg of vitamin C\n\n    Exclusion criteria related to the use of colchicine:\n12. Allergic to colchicine\n13. Myelodysplastic hypoplasia, or liver or severe renal failure\n14. Use of medication which may interact with colchicine (e.g., strong CYPsA4 inhibitors such as ketoconazole, strong P-glycoprotein inhibitors such as fluconazole)",{"count":621,"type":21},2000,[156],"This is a domain within the ACT-GLOBAL platform trial to compare the effectiveness of early and appropriate pharmacological interventions in acute intracerebral hemorrhage (ICH) to control secondary brain injury. Up to 2000 patients with presumed spontaneous supratentorial intracerebral hemorrhage (ICH) will be followed for 6 months (or death, if prior to 6 months).\n\nAdaptive interim analyses will be used, with statistical triggers to determine if any of the interventions are superior to control. The end of the trial is defined as the date that all participants have completed their 6-month assessment.\n\nA large amount of preclinical data indicates that the outcome from ICH is linked to the detrimental effects of breakdown substances from brain bleeds. However, there remains a lack of compelling evidence supporting the effectiveness of any pharmacological intervention that can mitigate the secondary cerebral injury. The INTERACT domain aims to assess the effectiveness of intravenous deferoxamine and low-dose oral colchicine, both individually and in combination, to standard of care alone, on improving functional outcome in patients with spontaneous supratentorial ICH.\n\nThose patients who meet eligibility criteria will be randomized to receive one of four interventions:\n\n1. No deferoxamine mesylate and no colchicine (labeled as control)\n2. Deferoxamine mesylate only: deferoxamine mesylate at a dose of 32mg\u002Fkg\u002Fday via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days.\n3. Colchicine only: 0.5mg of oral colchicine daily for 30 consecutive days.\n4. Both deferoxamine mesylate and colchicine: deferoxamine mesylate at a dose of 32mg\u002Fkg\u002Fday via intravenous infusion immediately (within 1 hour) post-randomization and continue for the following 2 consecutive days; plus 0.5mg of oral colchicine daily for 30 consecutive days.",[625,626,627,628,27],"Intracerebral Hemorrhage","Spontaneous Intracerebral Hemorrhage","Supratentorial Intracerebral Haemorrhage","Acute Intracerebral Haemorrhage",[91,27,630,625,631,632,633,634,635,636],"ICH","Platform Trial","Adaptive Platform Trial","Supratentorial ICH","secondary brain injury","deferoxamine mesylate","colchicine","2025-04-08",{"date":639,"type":32},"2025-04-10",{"date":641,"type":32},"2025-02-27",{"date":643,"type":21},"2028-01",{"name":103,"class":39},2,{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":654,"maxAge":239,"enrollmentInfo":655,"targetDuration":4,"studyType":22,"phases":657,"briefSummary":658,"conditions":659,"keywords":660,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":202},"100586037","direct-to-angio-approach-from-local-hospitals-based-on-a-point-of-care-blood-test-for-lvo-100586037","NCT06910163","Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO","Direct-to-angio Approach From loCal hOspitals Based on a PoInt-of-care bLOod Test for LVO (COPILOT): an Effectiveness Cluster Randomized Crossover Trial","COPILOT","Inclusion Criteria:\n\n* Age: 21 to 85 years old\n* Language: Speak and understand Spanish or English\n* Residence: Resident of Puerto Rico\n* Clinical presentation: Suspected acute stroke\n* Time of presentation: Monday to Friday, between 8:00 a.m. and 4:00 p.m.\n* Time of symptom onset: symptoms are known to have begun within the last 6 hours, OR last known to be well between 6 and 18 hours ago, confirmed by a reliable witness or healthcare professional\n\nExclusion Criteria:\n\n* Previous healthcare encounter:\n* Already assessed at another hospital, and ambulance admission is a transfer for continuing care OR\n* Received thrombolysis therapy before consent (e.g., tPA, alteplase)\n* Medical History: diagnosed with any of the following in the past 4 weeks: deep vein thrombosis (DVT), pulmonary embolism (PE), arterial embolism, stroke, transient ischemic attack (TIA), long bone fracture, major trauma, surgery under general anesthesia, or head injury requiring hospital admission within the last 4 weeks.\n* Modified Rankin Scale: Pre-stroke mRS ≥ 3\n* The patient is a pregnant woman\n* The patient is under legal custody or deprived of liberty in penitentiary institutions\n* The patient is unable to provide informed consent on their own and whose authorized legal representatives are unavailable in person or by telephone during recruitment","21 Years",{"count":656,"type":21},520,[24],"Direct-to-angio approach from loCal hOspitals based on a PoInt-of-care bLOod Test for LVO (COPILOT) is a multi-center, prospective, cluster-randomized crossover trial that will evaluate if the triage assessment to thrombectomy puncture time is shorter after performing the LVOne testing compared to current management standards in patients with suspected large vessel occlusion.",[27],[27,53,661,559,662,663,664],"LVOne Test","Large Vessel Occlusion (LVO)","Glial Fibrillary Acidic Protein (GFAP)","D-dimer","2025-03-27",{"date":667,"type":32},"2025-04-04",{"date":669,"type":21},"2025-05",{"date":671,"type":21},"2028-08",{"name":673,"class":39},"Juan Vicenty",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":678,"acronym":679,"eligibilityCriteria":680,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":681,"enrollmentInfo":682,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":684,"conditions":685,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":689,"completionDateStruct":691,"leadSponsor":692,"locationsCount":202},"100341051","the-bern-heart-and-brain-interaction-study---interaction-between-brain-and-heart-in-acute-ischemic-stroke-100341051","NCT03720522","The Bern Heart and Brain Interaction Study - Interaction Between Brain and Heart in Acute Ischemic Stroke","BEHABIS","Inclusion Criteria:\n\n* Informed consent as documented by signature.\n* Age: ≥ 18 and \\\u003C 86 years.\n* Acute ischemic stroke with symptom onset within 12 hours before admission to hospital.\n* Diagnosis of acute ischemic stroke with MRI with diffusion restriction as seen on diffusion weighted imaging.\n\nExclusion Criteria:\n\n* Pregnancy. A negative pregnancy test upon admission is required for all women with child-bearing potential.\n* Standard contraindication for performing MRI.\n* Severe renal failure (GFR \\\u003C40).","86 Years",{"count":683,"type":21},220,"Acute ischemic stroke is caused by blockage of blood vessels in the brain. Blood vessels can be obstructed by several different mechanisms and identification of this cause is essential to minimize the risk of recurrence.",[27],"2024-11-19",{"date":688,"type":32},"2024-11-22",{"date":690,"type":32},"2018-12-01",{"date":228,"type":21},{"name":693,"class":39},"Insel Gruppe AG, University Hospital Bern"]